Compare Apartment Investment and Management Co (AIV) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Crispr Therapeutics AG — how do they compare? Apartment Investment and Management Co trades at $2.65 (market cap $379.07M), while Crispr Therapeutics AG trades at $54.09 (market cap $5.22B). The key difference: Crispr Therapeutics AG is far larger — about 13.8× Apartment Investment and Management Co's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | CRSP | |
|---|---|---|
Market Cap | $379.07M | $5.22B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $76.78 |
52-Week Low | $2.59 | $44.34 |
Enterprise Value | $741.22M | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.61, up 0.77% today, with a bearish technical signal from moving averages despite a neutral RSI. The company reported a net income margin of 400.05% for 2025, driven by a $554.01M profit, though revenue declined to $138.49M. Recent news includes Dimensional Fund Advisors reducing its stake by 49.2% in Q1 2026 (Defense World, 2026-08-13).
Outlook is mixed: strong profitability and a low P/B of 0.77 suggest undervaluation, but inconsistent earnings history and bearish technicals pose risks. Analyst consensus is cautious with 33.3% buy ratings, highlighting volatility in real estate operations as a key concern for investors.
CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.
Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
